StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
AVAI

Avaí Bio, Inc.

AVAI OTC Services-Computer Processing & Data Preparation EDGAR ↗
$0.13
+0.00 +1.63%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$19.2M
Revenue (TTM) ⓘ
$276K
Net income (TTM) ⓘ
-$2.79M
EPS (TTM) ⓘ
$-0.01
P/E ratio ⓘ
—
Dividend yield ⓘ
20.00%
Free cash flow ⓘ
—
Cash ⓘ
$83.6K
Total assets ⓘ
$792K
Gross margin ⓘ
-14.6%
52-week range ⓘ
$0.10 – $0.80

AI briefing

from the latest 10-K, 10-Q and 8-K events

Avai Bio, Inc. is a micro-cap AI technology company that acquires and develops AI-based software and provides IT consulting services.

What they do

Avai Bio, Inc. (formerly Avant Technologies Inc.) specializes in acquiring, creating, and developing artificial intelligence technologies, and provides IT consulting services including full-stack software development, database management, data integration, project management, and cloud services. Its key assets include the Avant! AI acquisition and a Joint Venture and License Agreement with Ainnova Tech Inc. The company also operates Thy News LLC, a customizable news feed app available on Apple AppStore and Google Play Market.

Revenue drivers

  • IT Consulting Services — Provides a range of IT consulting services, but no specific revenue figures are disclosed for this segment.
  • Thy News App — A free news aggregation app with optional paid subscription features; had access to 149,000 processed news sources as of December 31, 2025.
  • AI Technology Solutions — Developing proprietary AI solutions based on unsupervised and supervised learning; revenue potential not yet demonstrated in reported financials.

Recent performance

For fiscal year 2026, the company reported a net loss of $1.7M and diluted EPS of -$0.01, compared to a net loss of $1.1M and -$0.01 in fiscal 2025. Operating cash flow was -$1.0M in 2026, an improvement from -$1.2M in 2025. Annual revenue for 2023 was $276,324, but no recent revenue figures are provided. As of June 30, 2026, cash and equivalents were $83,586, total assets $791,750, and total liabilities $4.0M, resulting in negative shareholder equity of $3.2M.

Strategy

The company plans to continue acquiring and developing innovative AI technologies, leveraging its Avant! AI and Ainnova Tech license. It aims to commercialize its AI platform that uses unsupervised clustering to prepare data for supervised learning, which it believes provides a true reasoning mechanism. The name change to Avai Bio, Inc. was completed in February 2026, with no strategic shift indicated. Management also intends to expand the Thy News application's user base and paid features.

Risks

  • Limited operating history — The company has a limited operating history in an evolving AI industry, making it difficult to forecast revenues and plan expenses.
  • Recurring losses and negative cash flow — The company has not achieved profitability and has generated negative operating cash flow in recent periods, raising doubt about its ability to continue operations.
  • Need for additional capital — The company expects to require additional capital to support growth, but such capital may not be available on acceptable terms, if at all.
  • Dependence on key personnel and acquisitions — The company depends on key personnel and the successful integration of acquisitions like Avant! AI and the Ainnova Tech license; failure could harm the business.

Outlook

Management expects to continue developing and marketing AI solutions and consulting services, but acknowledges uncertainty in achieving profitability. The company will require additional funding to sustain operations and growth. It intends to focus on expanding its product offerings and customer base, though no specific targets are provided.

Recent SEC filings

40 most recent
Annual, quarterly & current reports